ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 326

IL-1 Receptor Antagonis (IL-1Ra)-Fc Ameliorate Autoimmune Arthritis By Regulation of the Th17 Cells/Treg Balance and Arthrogenic Cytokine Activation

Hong Ki Min1, Sung Hwan Park2, Mi-La Cho3, Ji Hyeon Ju1, Seung-Ki Kwok4, Seon-Yeong Lee3, Seung Min Jung1, Kyung-Su Park5 and Jennifer Lee1, 1Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, 3Rheumatism Research Center, Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, St. Mary’s hospital, The Catholic University of Korea, Seoul, South Korea, 5Internal Medicine, St. Vincent Hospital, SuWon Gyeonggi-do, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Autoinflammatory Disease, IL-1, T cells, T-Regulatory Cells and osteoclastogenesis

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: : IL-1ß signalling has critical role on pathogenesis of various inflammatory arthritis including rheumatoid arthritis (RA). We aimed to investigate the therapeutic effects of human IL-1 receptor antagonist with Fc fragment (hIL-1Ra-Fc) on autoimmune arthritis and find out the possible mechanisms by which hIL-1RA-Fc has anti-arthritic effects in a murine model of RA and arthritis patient.

Methods: Collagen-induced arthritis (CIA) murine model was induced in DBA/1J mice. The levels of various cytokines were determined by using enzyme-linked immunosorbent assay. The joints of mouse were assessed for clinical arthritis score and histologic features. Th17 cells and Treg cells were stained by using antibodies specific for CD4, IL-17, CD25, and FoxP3. Osteoclastogenesis was determined by TRAP stain and real-time PCR.

Results: hIL-1RA-Fc reduced the clinical arthritis, histological inflammation and cartilage score in CIA model. The expression of proinflammatory cytokines, VEGF, and RANK were reduced in affected joint of hIL-1Ra-Fc treated mice. hIL-1Ra-Fc treated mice showed decreased number of Th17 cells with increased Treg cells in spleens. hIL-1Ra-Fc reduced Th17 cell differentiation by inactivation of STAT-3 signalling, reciprocally induced Treg cell differentiation through STAT-5 signalling. In addition, Suppression of gene expression of IL-17, TNF-α, RANKL and VEGF were decreased, while increased Foxp3 gene expression in PBMC of RA patients after administration of hIL-1Ra-Fc.

Conclusion: The anti-arthritis effects of hIL-1RA-Fc are associated with regulating balance between Th17 cells and Treg cells and with suppressing osteoclastogenesis and angiogenesis in affected joints.


Disclosure:

H. K. Min,
None;

S. H. Park,
None;

M. L. Cho,
None;

J. H. Ju,
None;

S. K. Kwok,
None;

S. Y. Lee,
None;

S. M. Jung,
None;

K. S. Park,
None;

J. Lee,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-1-receptor-antagonis-il-1ra-fc-ameliorate-autoimmune-arthritis-by-regulation-of-the-th17-cellstreg-balance-and-arthrogenic-cytokine-activation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology